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Abstract Vascular walls change their dimension and mechanical properties in response to injury such as balloon angioplasty and
endovascular stent implantation. Placement of bare metal stents induces neointimal proliferation/restenosis which pro-
gresses through different phases of repairwith time involving a cascadeof cellular reactions. These phases just likewound
healing comprise distinct steps consisting of thrombosis, inflammation, proliferation, and migration followed by remod-
elling. It is noteworthy that animals show a rapid progression of healing after stent deployment compared with man.
During stenting, endothelial cells are partially to completely destroyed or crushed along with medial wall injury and
stretching promoting activation of platelets, and thrombus formation accompanied by inflammatory reaction. Macro-
phages and platelets play a central role through the release of cytokines and growth factors that induce vascular
smoothmuscle cell accumulationwithin the intima. Smoothmuscle cells undergo complex phenotypic changes including
migration and proliferation from themedia towards the intima, and transition fromacontractile to a synthetic phenotype;
themolecularmechanisms responsible for this changearehighlighted in this review. Since studies in animals andmanshow
that smoothmuscle cells play a dominant role in restenosis, drugs like rapamycin and paclitaxel havebeen coatedon stent
with polymers to allow local slow release of drugs, which have resulted in dramatic reduction of restenosis thatwas once
the Achilles’ heel of interventional cardiologists.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Restenosis † Smooth muscle cells † Endothelial cells † Extracellular matrix † S100A4
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This article is part of the Spotlight Issue on: Biomechanical Factors in Cardiovascular Disease.
1. Introduction
Restenosis or the re-narrowingof the arteries occurs followingmechan-
ical injury, such as balloon angioplasty and endovascular stent implant-
ation. Placement of conventional, bare metal stents (BMS), which
requires the use of balloon, initiates immediately a variety of reactions
including de-endothelialization of the surface, crushing, and lifting of
the plaque from the underlying arterial wall, and tearing and stretching
of the medial wall, with eventual neointimal growth as a general
healing response. The initial reaction to the mechanical damage
inducedbystent implantationorballoonangioplasty is platelet activation
and thrombus formation accompanied by inflammatory reaction even in
the presence of dual antiplatelet therapy. However, the extent of plate-
let deposition is significantly higher in the absence of dual antiplatelet
therapy. This is followed by the activation of chemokines and cytokines
which lead to the proliferation and migration of smooth muscle cells
(SMCs) within the media and the intima. These cellular responses lead
to intimal thickening by SMCs and the surrounding extracellular
matrix (ECM) with or without the progression to restenosis.1,2
However, with the advent of drug-eluting stents (DES) since the early
to mid-2000, neointimal proliferation and restenosis have been
dramatically reduced through the suppression of SMC proliferation
and migration accompanied by delayed healing. Differences between
animalmodels andhuman responses exist such as theunderlying athero-
sclerotic plaque and its influence on the success and failure of these
devices in man; nonetheless, important mechanisms have been eluci-
dated by animal studies and will be discussed where appropriate.
2. Pathophysiology of restenosis in
stented arteries
Restenosis is an exaggerated response, and is defined as .75% cross-
sectional area luminal narrowing of the stented area by neointimal
tissue consisting of SMCs and proteoglycan-collagenous matrix. The
time course of re-endothelialization and neointimal growth after stent
deployment are different between animal species (e.g. in pig and
rabbit) and human iliac and coronary arteries (Figure 1).3,4 In animal
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models, peak neointimal growth is observed at 28 days following BMS
placement, whereas in humans, it is identified at 6–12 months
(Figure 2).4 In the animal models with normal underlying media,
restenosis is an uncommon response and only occurs in the presence
of severe injury to the underlying medial wall with tearing and a
profuse inflammatory response. In pathological human studies, its inci-
dence is high: 30–40%, and is usually a consequence of severe injury
and exaggerated inflammatory response. Recently, we have also
shown that atherosclerotic change within the neointima can occur but
usually only after 2 years of stent implantation.5
The best animal model that more closely simulate human disease is
the porcine coronary artery model; however, the rate of healing is ex-
tremely rapid with greater proliferation when compared with man.
For endothelialization studies, we have used the rabbit iliac artery
model which has a slightly slower rate of re-endothelialization when
compared with the porcine model.3 Other smaller models like the rat
andmice have been used but the arteries are too small and the flow dis-
turbances too great due to thick struts that it is not possible to extrapo-
late the results to man.
Cellular cascade response to mechanical vascular injury initiated im-
mediately after stent deployment can be divided into three different
time phases: an early phase consisting of platelet activation and
inflammation, followed by an intermediate phase of granulation tissue
Figure 1 BMS healing in animals vs. humans. Line plot showing the
temporal relation of peak neointimal growth in animals andhumans fol-
lowing the placement of bare stainless steel stent. The plots are pre-
dominantly derived from morphometric analysis of pig and human
coronary stents. In animals, peak neointimal growth in stainless steel
stents is observed at 28 days, compared with 6–12 months in
humans. (Reproduced with permission from Virmani et al.4)
Figure 2 Arterial healing following balloon expandable BMS implantation in human coronary arteries. (A) Platelet-rich thrombus (arrows) is identified
arounda stent strut (*) 1dayafter theplacementofDriver stent. (B)Afibrin-rich thrombus (arrowhead) is focally present arounda stent strut1dayafter the
placement of Express stent. (C–F ) Platelet- (arrow) and fibrin- (arrowheads) rich thrombus (C) with numerous inflammatory cell infiltration around stent
struts (double arrows, C–E) and focal endothelialization (F ). Five days after the placement of Multi-Link Vison stent. Giant cells are occasionally observed
(arrows,D). The presence of inflammatory cells consisting of neutrophils and lymphocytes (boxed area inD) are highlighted in (E andG– I ). Early neointima
present 23 days after Multi-Link Vision stent placement. (G) Intimal cells within extracellular matrix seen above the stent strut. (H) KP-1 immunostaining
identifying macrophages (arrows) adjacent to the strut at base of neointima. (I) Actin staining identifying smooth muscle cells close to luminal surface of
neointima (arrows). (J and K ). Smooth muscle cell-rich neointima in stented coronary artery (duration .6 months). Actin staining shows smooth
muscle cells close to luminal surface of the neointima in (I ). (A–G) are stained with haematoxylin and eosin, while (J ) is stained with Movat pentachrome.
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corresponding to SMC migration and proliferation, and a late phase of
tissue remodelling.1,6,7
2.1 The early phase
In the early phase after stent deployment, endothelial cells (ECs) arepar-
tially to completely destroyed or crushed promoting activation and ag-
gregationof platelets, infiltration of circulating leucocytes, and release of
growth factors and cytokines.1,2,8
2.1.1 Endothelium injury
It is noteworthy that the early event after BMS implantation involves
endothelium injury.9 The response of the endothelium to stenting can
be divided into three phases: endothelial denudation, re-endothelializa-
tion, and/or neoendothelium.6 Indeed, in human, in response to coron-
ary stent implantation, complete to partial destruction of the EC layer is
observed, this initiates the formationof a thin layerof thrombus covering
the vascular and stent surface (in the presence of dual antiplatelet
therapy and heparin). Complete coverage of the neointima by vascular
ECs occurs several weeks after stenting.6 In animal models, many
studies have demonstrated that dysfunction of the regenerating ECs
after stent implantationpromotesmobilizationof bonemarrow-derived
endothelial progenitor cells to accelerate vascular repair through rapid
re-endothelialization and attenuate neointimal formation.4,10 The con-
tribution of the circulating endothelial progenitor cell has not been
well demonstrated in patients undergoing stenting although their mobil-
ization has been demonstrated to stent site in arteriovenous shunts and
an increase in circulating endothelial progenitor cells has been reported
with the use of statins.10
2.1.2 Inflammatory response
Endothelium injuryand foreignbodystentplacement lead to the response
of the activation of platelets and their deposition at the site of the lesion,
with recruitment of circulating leucocytes.2,4 Leucocyte–platelet interac-
tions are critical in the initiation and progression of neointimal formation.
Many studies have shown the importance of inflammation as an early
event after stenting in different animal models using specific antibodies
to leucocytes (CD45), macrophages (CD14), and monocytes (CD115).
The number of adherent monocytes is correlated with neointimal area.
Few investigators have correlated the number of macrophages in the
neointima to the extent of neointimal formation and have shown that as
the inflammation increases so does neointima increase. In human
studies, a strong link has been demonstrated between an early chronic in-
flammation and intimal thickening in stented coronaries.11Others believe
that neutrophils and notmacrophages play an important role in the induc-
tionof SMCproliferation and intimal thickening. In the rabbitmodel,Welt
et al.12 have shown that with the use of monoclonal antibody to Mac-1
there was a reduction in neutrophil infiltration and decrease in SMC pro-
liferation.
2.2 Granulation tissue formation
The ECs proliferate and migrate over the injured areas while SMCs and
macrophages replace the fibrin clot with granulation tissue. The newly
formed vascularized tissue includesmacrophageswhich are responsible
for phagocytosis of cell debris as well as secretion of growth factors
chemokines and cytokines. Themacrophages enhance the inflammatory
response, but along with platelets and ECs serve to secrete growth
factors. These growth factors including fibroblast growth factor (FGF),
insulin-like growth factor (IGF), transforming growth factor beta
(TGF-b), platelet-derived growth factor (PDGF), and vascular
endothelial growth factor (VEGF) all facilitate the SMC and EC prolifer-
ation which are required for the wounded surface to heal.
2.3 Tissue remodelling phase
The hallmark of this phase is the modification of SMCs (see in what
follows) activated by growth factors/cytokines produced by the
injured endothelium and media, platelets, and infiltrated inflammatory
cells as well as by the compressive forces generated in the vessel wall
by the stent placement along with low shear stress-induced by stent
struts. SMCsundergo complex changes includingmigration and prolifer-
ation from the media towards the intima. Proliferation of SMCs in the
media and the subsequent migration into the intima13 require the tran-
sition of SMCs from a contractile to a synthetic phenotype (see in what
follows) with the eventual ECM deposition in the intima.14 The ECM
plays an important role as it interactswith cells to influence adhesion,mi-
gration, proliferation, and remodelling of thewound. In the first phase of
matrix formation is the formationof ‘provisionalmatrix’ which is formed
by the plasma proteins such as fibrin, fibrinogen, and fibronectin.15 The
ECM allows for inflammatory cells like the macrophage and SMCs to
adhere and begin the repair process. The SMCs secret hyaluronan and
proteoglycans, especially versican that interact and stabilize the
fibrin-enriched ECM. This matrix allows more SMCs to bind and prolif-
eratewhile also trapping inflammatory cells that releasematrix metallo-
proteinases (MMPs) that digest the hyaluronan so that a more
permanent matrix collagen type I and III production can occur allowing
the wound to completely heal with eventual fibrosis. Collagen also ad-
versely affects the SMCs by arresting its proliferation and eventually
resulting in altered contractile forces with eventual SMC apoptosis
and cell loss. These processes are closely interrelated and difficult to
separate in sequential phases.
3. Prospective view on how to
prevent in-stent restenosis
Prior to the introduction of drug-eluting stents for the reduction of re-
stenosismanyoral pharmacological agents had shownpromise in animal
studies but all failed when tried in man. The concept of drug therapy to
reduce restenosis began in theeraof balloon angioplasty.Oneof thefirst
concepts was that platelets and thrombi were responsible for SMCpro-
liferation through the release of PDGF, as a result numerous antiplatelet
and antithrombotic drugs were tried with uniform failure in man al-
though each had shown promise in animal models. This leads to
search for a better understanding of restenosis after vascular injury
that occurs during percutaneous coronary intervention (PCI).
Three basic mechanisms have been identified: elastic recoil, negative
remodelling, and neointimal hyperplasia. Coronary stenting prevents
elastic recoil but is associatedwith greater neointimal hyperplasia, i.e. al-
though many cytokines and mediators are involved, the final common
pathway is the entry of SMCs into the cell cycle. It has now been well
shown in the porcine model that neointimal hyperplasia is proportional
to the extent of vascular injury and it has also been validated in man.
SMCs in the media of normal arteries are quiescent with a very low
rate of proliferation (SMCs aremostly in quiescent and non-proliferative
phase G0); however, once injury occurs, there is an imbalance between
stimulatory growth factors and cytokines (e.g. PDGF, interleukin-1, -6,
and tumour necrosis factor-a) and inhibitory factors (e.g. endothelial-
derivednitricoxide, heparin sulfateproteoglycans) inducing SMCactiva-
tion, i.e. the SMC change from a quiescent contractile phase into a
In-stent restenosis 355
synthetic phenotype.Once activated the SMCs then enter into the cycle
of division which is divided into four phases: G0, G1, S, G2, and M. A
number of growth factors like FGF-2, epidermal growth factor, PDGF,
and IGF are responsible for the initiation of VSMC proliferation via the
tyrosine kinase receptors (TKRs) (Figure 3). The tyrosine kinase recep-
tor can also activate the mitogen-activated protein kinase (MAPK)
pathway. The cell cycle is the final common pathway that leads to
intimal hyperplasia following vascular injury and therefore targeting
the regulators of the cell cycle with either cytostatic drugs which alter
the expression of cell-cycle promoting or inhibitory proteins or
through cytotoxic drugswhich result in cell death and necrosis, inducing
inflammation and ultimately may even promote restenosis.
The better understanding of the importanceof SMCproliferation and
migration resulted in the use of immunosuppressant drug like sirolimus
and its analogues (everolmus, zotarolimus, biolimus A9, myolimusand,
and others) delivered on stents through the use of polymers. Sirolimus
inhibits the mammalian target of rapamycin and prevents the degrad-
ation of p27kip1, a cyclin-dependent kinase inhibitor that plays an im-
portant role in regulating vascular SMC migration and proliferation.5,6
More pertinent to the process of arterial healing, sirolimus is also a
potent inhibitor of EC proliferation by deactivating the p70 S6 kinase
pathway, an essential step for cell-cycle progression in response to
growth factors. The best results have been reported with the use of
the cytostatic drug than cytotoxic drugs16 (Figures 3 and 4); however,
both have the short-coming of being non-specific in that they inhibit
the proliferation of both SMCs and ECs and also permanent polymers
induce inflammation. As stated earlier and shown in Table 1, cytotoxic
drugs like actinomycin D delivered via permanent polymer and
Figure 3 Overview of the molecular mechanisms of restenosis and their inhibitors. The normal coronary artery is injured secondarily from ballooning
and stenting resulting in endothelial cells (EC) loss followedbymural thrombus consisting of platelet aggregationwith fibrin deposition. The plateletswithin
the thrombus release a number of chemokines essential for the initiation of inflammation. This includes activation of P-selectin and integrins such as
b2-integrin Mac-1 and thrombin. Local production of chemokines like interleukin (IL)-1, IL-6, interferon (IFN)g, and tumour necrosis factor-alpha
(TNF-a) by macrophages result in the induction of inflammation at the injury site. The injury is not only to the endothelium but also to the underlying
medial wall. There is an imbalance between stimulatory growth factors (PDGF, FGF, TGF-b, and IGF-1) and chemokines and the inhibitory factors like
endothelial-derived nitric oxide and heparin sulfate proteoglycans that result in the activation of smooth muscle cells (SMCs). The SMCs within the
media transform from a quiescent contractile to a synthetic cell which not only proliferate but also migrate into the intima. Within the intima they
further proliferate but also secrete extracellular matrix. SMC proliferation involves cell division with different cyclins that are required at different steps
of the cell cycle. CDK (cyclin-dependent kinase) activity is also regulated by cell-cycle inhibitory proteins called cyclin-dependent kinase inhibitors
(CKIs), which counteract CDK activity. SMCmembranes are also stimulated by several classes of tyrosine kinase receptors (TKR). One of the intracellular
signalling pathways involves the phosphatidylinositol (PI)3-kinase (PI3K) pathway. PI3K is a lipid kinase that phosphorylates PI. The dominant lipid product
generated by PI3K—PI 3,4-biphosphate (PIP2) and PI 3,4,5-triphosphate (PIP3), the latter recruits phosphoinositide-dependent kinase-1 and Akt. Akt is
then capable of phosphorylating the mammalian target of rapamycin (mTOR). The yellow squares show the various inhibitors and at which site of the
cell cycle they are involved, especially sirolimus and its analogues which inhibit mTOR, whereas paclitaxel blocks microtubular mechanisms. The insert
on the left is reproduced with permission from Charron et al.16
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high-dose paclitaxel coated directly on a stent without the use of
polymer failed in clinical trials because of toxic effects and restenosis
at 6 months. The anti-proliferative drug tacrolimus failed because it is
100 times less potent for inhibitory activity on human SMCs. The
future may lie in the use of totally erodible polymers without the use
of metal, and therefore drug effects will not persist and there is
absence of persistent inflammation associated with greater neointimal
formationor induces atherosclerotic changesobserved inmetal-stented
segments. Also, one can envision the use ofmore specific drugs that only
target SMCs or use of molecules that enhance endothelialization and
gene therapy.
4. Role of EC shear stress
Local haemodynamic factors, in particular low endothelial shear stress
has been well recognized as the region where atherosclerotic plaques
form and these sites typically include bifurcations at the outer wall and
inner curvatures of the arteries. It has been shown that in regions of dis-
turbed flow, the balance of gene expression is tipped towards athero-
susceptibility. Total endothelial protein kinaseC activity in the disturbed
flow regions is 145–240% that of undisturbed flow locations (P, 0.05),
whereas theundisturbedflow regions are not significantly different from
each other.17 ECs express proinflammatory mediators like vascular
cell adhesion molecule-1 (VCAM-1) which activates p38 and c-Jun
N-terminal kinase MAPK by phosphorylation. MAPK phosphatase 1
expression is induced by shear stress, while VCAM-1 is down-
regulated.18 Similarly, in stented arteries, a stent that protrudes into
the lumen will alter the coronary flow and geometry and results in
changes in local shear stress distribution.19 This results in the develop-
ment of vorticeswhere the flowhas to turn sharply promoting fluid sep-
aration. The blood travelling tangentially to the stent strut surfaces
induces large shearing force20 and at these sites, platelet activation
occurs with the release of thromboxane and adenosine diphosphate
and other procoagulant factors which at critical concentrations activate
the coagulation cascade. The destruction of the endothelium during
balloon angioplasty and stenting results in the loss of the endothelium
removing the benefit of the anti-coagulants produced by the endothe-
lium such as nitric oxide, prostacyclin, tissue factor pathway inhibitor,
tissue plasminogen activator, thrombomodulin, and heparan. It has
been shown in animal experiments that increasing wall shear stress
Figure 4 Principal sites of action of anti-proliferative drugs. Repro-
duced with permission from Charron et al.16
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Table 1 Summary of clinical trials of DES (modified fromCharron et al.16)
Study (reference) Design Number of points In-stent late loss (mm),
DES vs. BMS
In-stent binary restenosis
(%) DES vs. BMS
Sirolimus
RAVEL Multicentre, PRDBC 238 20.01 vs. 0.80, P, 0.001 0.0 vs. 26.6, P, 0.001
SIRUS Multicentre, PRDBC 1101 0.17 vs. 1.00, P, 0.01 3.2 vs. 35.4, P, 0.001
E-SIRUS Multicentre, PRDBC 350 0.20 vs. 1.05, P, 0.0001 3.9 vs. 41.7, P, 0.0001
C-SIRUS Multicentre, PRDBC 102 0.12 vs.1.05, P, 0.001 0.0 vs. 45.5, P, 0.001
Paclitaxel
DELIEVER Multicentre, PRSBC 1043 0.81 vs. 0.98, P ¼ 0.0025 14.9 vs.20.6, P ¼ 0.076
TAXUS II* Multicentre, PRDBC 267 (slow) 0.31 vs.0.79, P, 0.001 2.3 vs. 17.9, P, 0.001
TAXUS II** Multicentre, PRDBC 269 (mod) 0.30 vs.0.77, P, 0.001 4.7 vs. 20.2, P, 0.001
TAXUS IV* Multicentre, PRDBC 1314 (slow) 0.39 vs.0.92, P, 0.0001 5.5 vs. 24.4, P, 0.0001
Everolimus
FUTURE I Single centre, PRSBC 42 0.11 vs.0.85, P, 0.0001 0.0 vs.9.1, P ¼ NS
FUTURE II Multicentre, PRSBC 64 0.12 vs.0.85, P, 0.0001 0.0 vs. 19.4, P ¼ 0.039
SPIRIT I Multicentre, PRDBC 60 0.10 vs. 0.84, P, 0.0001 0.0 vs. 26.9, P ¼ 0.01
SPIRIT III Multicentre, PRDBC 1002 0.14 vs. 0.28, P ¼ 0.004 4.7 vs. 8.9 P ¼ 0.07
SPIRIT IV Multicentre, PRDBC 3687 – TLF ¼ 4.2 vs. 6.8, P, 0.001
Tacrolimus (PRESENT I) Single centre, registry 22 0.81+0.39 19.0
17-beta-estradiol (EASTER) Single centre, registry 30 0.54+0.44 6.7
Actinomycin D (ACTION) Multcentre, PRSBC; high-dose group 360 0.93 vs.0.76, P ¼ 0.03 17.9 vs. 11.0, P ¼ 0.38
The cell cycle: a critical therapeutic target to prevent vascular proliferation.
ACTION, ACTinomycin eluting stent ImprovesOutcomes by reducing Neointimal hyperplasia; C, Canada; E, Europe, EASTER, ESTrogen and Stents to Eliminate Restenosis; FUTURE, First
Use To Underscore restenosis Reduction with Everolimus; NS, not significant; PRDBC, Prospective, randomized, double-blind, controlled; PRESENT, PREliminary Safety Evaluation of
Nanoporous Tacrolimus-eluting stents; PRSBC, Prospective, randomized, single-blind, controlled; RAVEL, Randomized studywith the sirolimus-eluting VElocity balloon-expandable stent in
the treatment of patients with de novo native coronary artery Lesions; SIRIUS, SIRolimUS-eluting stent in de novo native coronary lesions; TLF, target lesion failure.
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from 0.38 to 0.82 N/m2 reduces neointimal hyperplasia21 and did not
change inflammation or injury score. Also, low flow velocity (shear
stress) inhibits re-endothelialization of the vessel surfaces and struts.
Similarly, it has been shown that when cultured SMCs are in synthetic
phenotype, they respond to shear stress in a similarmanner to endothe-
lial cells, altering theproductionof growth factors.High shear stress inhi-
bits SMC proliferation in vitro via TGF-b1 and tissue-type plasminogen
activator.22
Low endothelial shear stress and/or disturbed flow modulate EC
mechanosensors (endothelial mechanotransduction). Deformation of
the luminal surface of ECs affects structural components such as caveo-
lae or glycocalyx, and is transmitted throughout the EC via the cytoskel-
eton to intercellular junction complexes and transmembrane proteins
(such as cadherins, catenins, platelet EC adhesionmolecule-1, integrins).
This results in the autophosphorylation of focal adhesion kinases and
other MAP kinases that induce the expression of atherogenic genes
such as PDGFs responsible for the activation of SMCs23,24
5. Role of mechanical stretch
on SMCs
To maintain a patent lumen and prevent elastic recoil by the artery, im-
plantation of the stent stretches the vessel; this yields extremely high,
non-physiological, circumferential, and radial wall stress (Laplace
law).25 These compressive forces produced by stent placement activate
intracellular pathways in vascular SMCs (SMC mechanotransduction).
Mechanical stretch is transmitted to the SMCs through focal adhesion
that links the ECM and the intracellular cytoskeleton.26,27 Focal adhe-
sions are macromolecular protein complexes consisting of transmem-
brane integrins that are associated with intracellular adaptors (paxillin,
vinculin, talin) and signalling proteins (focal adhesion kinases). In turn,
SMCs undergo phenotypic adaptation. Mechanical stretch induces
enhanced SMC proliferation and migration by activating RhoA/Rho
kinase, MAPK, TKR (e.g. PDGF receptor), and PI3K/Akt pathways.
Stretch-induced SMC proliferation could be mediated by IGF-1,
PDGF-BB, and FGF-2. It has been reported that MMPs have differential
responses to stretch. The effect of mechanical stretch on SMC survival/
apoptosis is controversial. Interestingly, mechanical stretch induces
apoptosis on differentiated SMCs but not on proliferating SMCs.Never-
theless, themechanismscontrolling the responseof SMCstomechanical
stress remain to be clarified.
SMCs which are embedded in the vascular wall may be exposed to
blood flow and shear stress. However, early after endothelial denuda-
tion, the superficial layer of SMCs directly in contact with the blood
flow is rapidlyactivatedanddedifferentiated,whilewhen intimal thicken-
ing appears, the majority of medial SMCs are no longer activated. This
result indicates that blood flow acts on arterial SMCs.28,29 By mechan-
isms similar to those described for ECs (discussed earlier) shear stress
promotes PDGF-BB and FGF-2 release fromSMCs and in turn their pro-
liferation andmigration. Shear stress can alsomodulate SMCs fromcon-
tractile to synthetic phenotype.30
6. Role of SMC heterogeneity
During their accumulation in the intima, SMCs undergo complex
changes and switch from a contractile (rich in contractile elements,
low proliferative, and migratory activities) to a synthetic phenotype
(rich in endoplasmic reticulum, high proliferative, and migratory
activities).
6.1 Features of SMC phenotypes
The contractile phenotype is typical of SMCs in healthy artery wall and
corresponds to differentiated SMCs; these SMCs contain many micro-
filament bundles and their main function is the contraction–relaxation
of the vessel. They express well-defined differentiationmarkers belong-
ing to the cytoskeletal protein family, which are responsible for cell con-
traction. Among them, a-smooth muscle actin (a-SMA), the actin
isoform typical of vascular SMCs, desmin, an intermediate filament
protein expressed in all muscle cells, and SM myosin heavy chains
(SMMHCs) isoforms SM1 and SM2, specific of vascular SMCs, are the
most studied.14,31,32 Their expression is dependent on different cis–ele-
ments in their promoter region that are activated by specific binding
factors; in particular the CArG (i.e. CC[A/T-rich]6GG) sequence
motif binds serum response factor and myocardin.33 a-SMA is
expressed in vascular SMCs even at early stage SMC lineages of develop-
ment, and is only exceptionally absent in SMCs, therefore representing
the most widespread marker of vascular SMCs, whereas desmin and
SMMHCs are markers of well-differentiated SMC markers. Other less
extensively studied cytoskeletal proteins, such as smoothelin, SM22a,
calponin, heavy-caldesmon, and meta-vinculin, serve as late-
differentiation markers (Figure 5). Smoothelin, an a-SMA binding
protein, exists in two isoforms: smoothelin-A (59 KDa) and
smoothelin-B (110 KDa); the B isoform is predominantly expressed in
vascular SMCs. Smoothelin-B plays a crucial role in vascular SMC
Figure 5 Schema showing smooth muscle cell phenotypic changes
after stent implantation. Mechanical vascular injury initiated after
stent implantation induces cellular cascade response. Endothelium
injury activates platelet deposition at the site of lesion, which induces
recruitment of inflammatory cells as precursors to intimal thickening
formation. This leads to the activation of smoothmuscle cell migration,
proliferation, and phenotypic transition from contractile to synthetic
phenotype. Transition from a contractile to a synthetic phenotype is
associated with changes in smooth muscle cell gene/protein expres-
sion: decrease of contractile smooth muscle cell gene/proteins (in
blue) and increase of smooth muscle cell synthetic gene/proteins (in
red). Well-known growth factors involved in contractile to synthetic
phenotypic switch are mentioned.
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contraction by still undiscovered mechanisms besides being a reliable
marker of the contractile phenotype.34
The synthetic phenotype is typical of SMCs in themedia of developing
arteries and intimaof pathological arteries (atherosclerotic and resteno-
tic lesions) and corresponds to poorly differentiated or dedifferentiated
SMCs. It is characterized by a cytoplasm with a predominance of rough
endoplasmic reticulum and contains a well-developed Golgi apparatus.
These changes are correlated to the decrease or loss of the above-
mentioned SMC differentiation markers and the ability of SMCs to
produce ECM proteins.
The question remains openwhether any SMCs of themedia could be
activated towards a synthetic phenotypeoronly a pre-existing SMCsub-
population is prone to accumulate into the intimal thickening. This pos-
sibility is based on the observation that the atheromatous plaque has a
monoclonal or oligoclonal origin.35,36 This notion has been reinforced
by thedescriptionofmorphologically distinct SMCpopulations.37 Initial-
ly, two populations were identified in vitro in the rat carotid artery and
aorta: (i) a spindle-shaped (S) phenotype obtained from the normal
media and (ii) an epithelioid (E) phenotype isolated from the intimal
thickening 15days after endothelial injury.We isolated SMCclonesexhi-
biting S- and E-phenotypes in the rat aorta. E-SMC clones are prevalent
in balloon-induced intimal thickening and represent an atheroma-prone
phenotype. Distinct SMC phenotypes have been described in vessels of
other species such as cow pulmonary artery.38 From the normal media
of the porcine coronary artery, we isolated two distinct populations, S-
and R-SMCs (in this case the rhomboid [R]-SMCs are similar to the rat
E-SMCs).39 In the same model, we also demonstrated that a
stent-induced intimal thickening yields a large proportion of R-SMCs.
R-SMCs share similar featureswith rat E-SMCs, i.e. high proliferative,mi-
gratory, and proteolytic activities and a dedifferentiated phenotype indi-
cating that they represent a likely candidate for the formation of intimal
thickening and hence an atheroma-prone phenotype.
Exporting the concept of SMC heterogeneity from animal models to
human has been hampered by the limited availability of human arterial
SMCs and difficult experimental standardization. As a result, the isola-
tion of differing SMC subpopulations in humans has been sporadically
reportedover the last decade.37 Themost conclusivework todate dem-
onstrating the presence of SMC populations in human is based on the
finding that E-SMCs can be cloned from the media of undiseased arter-
ies.40Theexistenceofdistinct SMCsubpopulationshasbeen reported in
saphenous vein of non-diabetic and diabetic patients.41
Saphenous vein SMCs fromdiabetic patients exhibited anR-phenotype
and were more migratory, but less proliferative, when compared with
those from non-diabetic patients.
The role for adventitial myofibroblasts in neointima formation in re-
stenosis after balloon angioplasty or stent placement, as well as in the de-
velopment of atherosclerosis, has long been controversial. Some early
studies had suggested that the migration of adventitial myfibroblasts to
themedia and intimawaspivotal to neointima formation, including in rest-
enotic lesions after stent placement;42,43 recent evidence has corrobo-
rated the notion of a negligible contribution of myfibroblasts to this
process.44,45 Nevertheless, the study of SMC differentiation markers in
differentwell-characterized human coronary lesions, including restenotic
lesions after stent implantation, showed that coronary intimal SMCs
exhibit a phenotypic profile typical of myofibroblasts,46 a stromal cell
crucial for wound healing and fibrosis development. Myofibroblasts
sharewith SMCs the expression ofa-SMA. SMC-to-myofibroblast differ-
entiationmaycontribute toplaqueremodelling, inparticularbyproducing
ECM component similar to that of wound healing and fibrotic tissues.
It iswell accepted that SMCswithin the intimamigrate fromthemedia.
However, studies have suggested the role of adult vascular progenitor
cells in the development of atherosclerosis and vein graft atheroscler-
osis.47,48 SMC progenitor cells have been mainly identified in the bone
marrow (multipotent vascular stem cell progenitors and mesenchymal
stem cells), in the circulating blood, and in the adventitia (resident
SMC progenitor cells). These progenitor cells have the ability to differ-
entiate into SMCs.49,50 Although SMC progenitors could play a role in
the development of restenotic lesions, their contribution to human
in-stent restenosis has not been clearly demonstrated up to date.
6.1.1 S100A4
The comparison of S- and R-SMCs by 2D-gel electrophoresis followed
by tandem mass spectrometry allowed us to identify S100A4 as being a
marker of the R-SMC population in vitro.51 S100A4 is also a marker of
intimal SMCs in vivo, both in pig and man: it is strongly expressed in
intimal SMCs of porcine coronary artery stent-induced intimal thicken-
ing and of human atherosclerotic and restenotic lesions, whereas it is
hardly detectable in the underlying media of these lesions.51 S100A4 is
also up-regulated in arterial SMCs of childrenwith pulmonary hyperten-
sion.52More recently,wehaveobserved thatmedial SMCsofhumansac-
cular intracranial aneurysms exhibit a dedifferentiated phenotype as
demonstrated by decreased a-SMA and SMMHC expression, dis-
appearance of smoothelin, and the unexpected strong up-regulation
of S100A4 when they are compared with that of non-aneurysmal arter-
ies. Therefore, S100A4 represents a reliable marker of the synthetic/
dedifferentiated SMC phenotype in vivo. Nevertheless, the possibility
that a distinct SMC subpopulation is present in the healthy artery
remains to be demonstrated.
S100A4 is a small calcium-binding protein,53,54 knownas amediatorof
cancer metastasis.54 S100A4 is involved in cell proliferation and migra-
tion by inhibiting the phosphorylation of target proteins in a calcium-
dependent manner such as non-muscle myosin heavy chains and
p53.54–56 As an extracellular protein, S100A4 through the receptor
for advanced glycation end products (RAGE)55 induces migration of
various cells including tumour cells57,58 and ECs and is correlated with
increased MMP production.57,58 Some experiments suggest that
S100A4 could be involved in SMC phenotypic changes. Extracellular
S100A4 leads to human pulmonary artery SMC proliferation andmigra-
tion through NF-kB activation in a RAGE-dependent manner.59,60
S100A4has alsobeendetected in the culturemediumofhumanpulmon-
ary artery SMCsunder sustainedhypoxia: its blockadewith S100A4neu-
tralizing antibody attenuates SMC migration.51,61 We observed that
S100A4 is up-regulated in migrating R-SMCs and is implicated in
porcine R-SMC proliferation.51 Taken together, a better understanding
of S100A4 expression, release, and regulation in the SMCs will help to
shed light on the mechanisms of SMC phenotypic changes and accumu-
lation in the intima.
6.1.2 Other genes and/or proteins
Osteopontin, an ECM protein involved in bone mineralization is a
marker of rat E-SMCs. In vivo, it is transiently up-regulated in rat experi-
mentally induced intimal thickening and accumulates in calcified areas of
the human atheromatous plaque.62 Connexin 43, a component of gap
junction channels, is strongly expressed in human and mouse athero-
sclerotic plaque,63,64 and porcine coronary artery stent-induced
intimal thickening.65 This correlates in vitro with the high expression of
connexin 43 in R-SMCs.65 Interestingly, connexin 43 down-regulation
reduces atherosclerotic plaque development in mice.63,64 Recently,
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we have demonstrated that olfactomedin-like 3, a novel angiogenic
factor involved in pericyte migration and coverage of tumour vessels,
is elevated in R-SMCs, whereas it is undetectable in S-SMCs.66 Studies
of these proteins could give further insight into the mechanisms of
SMC phenotypic modulation.
MicroRNAs (miRNAs) are short non-coding single-strand RNAs,
which regulate post-transcriptionallymany genesbybinding to the3′ un-
translated regions of target mRNAs. Very recently, some of them have
been directly implicated in SMC phenotypic transition and intimal thick-
ening formation. In particular, miR-145 is a marker of differentiated
SMCs. Overexpression of miR-143 and miR-145 promotes SMC differ-
entiation in vitro.67 miR-145 is reduced in experimentally induced intimal
thickening in the rat carotid artery.68 Besides, neointimal formation is
reduced in miR-143 and miR-145-knockout mice following carotid
artery ligation.69 Quite in contrast, miR-221 and miR-223 are
up-regulated in proliferating SMCs in vitro and in intimal SMCs in vivo
after balloon-injury of rat carotid arteries.70
6.2 SMC proliferation and migration
SMCproliferation andmigration are essential processes in experimental
intimal thickening, atherosclerotic and restenotic lesion formation. Pro-
liferative and migratory activities have been studied in the distinct SMC
phenotypes identified in vitro. Although they stop growing at confluence
as a result of cell-contact inhibition, animal E- and R-SMCs showa higher
proliferative activity than S-SMCs. It is noteworthy that growth in the
absence of serum has been observed in rat E-SMCs and cow
R-SMCs.71 Rat E-SMCs produce PDGF-BB, which is a potent SMC
mitogen.72 Pig R-SMCs do not display autonomous growth;39 in this
respect, theyare similar tohuman.Apoptosis is an importantmechanism
in the regulation of intimal thickening evolution. An enhanced suscepti-
bility of E-SMCs to apoptosis induced by reactive oxygen species,73 ret-
inoic acid, and antimitotic drugs74 has been described.
Cell migration, a major event of the intimal thickening, is a complex
process that includes the degradation of ECM by proteolytic enzymes.
In pig,39 rat,75 and man,40 E- and R-SMCs exhibit a higher migratory ac-
tivity comparedwith S-SMCs. This is correlated to high tissue-type plas-
minogen activator activity in rat E-SMCs76 and high urokinase activity in
pig R-SMCs.39 Likewise, rat E-SMCs may produce plasminogen activa-
tors, and MMP-2 under particular growth conditions.77 Taken together,
the studies demonstrating the enhanced proliferative, migratory, and
apoptotic activities of E- and R-SMCs in various species fit well with
the expected features of participants in intimal thickening (Figure 5).
6.3 SMCs and ECM production
ECMof the intimal thickening is synthesized by neointimal SMCs. Itmod-
ulates important events during the evolution of the restenosis process,
including cell proliferation, migration, growth factor expression, and re-
modelling. ECM of the intimal thickening to a great extent differs from
the ECM of the underlying media that mainly contains fibrillar collagen
I and III, proteoglycans and thick fibres of elastin.78 ECM of the intimal
thickening consistsof varying concentrationsof proteoglycans (versican,
biglycan, and decorin), hyaluronan, and fragmented collagen (types I and
III). In stented human coronary arteries for over 18 months, the ECM
composition is similar to wound healing or fibrotic tissues. The neoin-
tima remodels over timewith changes in proteoglycans, such as increase
of decorin, and replacement of type III collagen with type I collagen.78
This phenomenon is accompanied by reduced SMC density.79
Intimal SMCs have the ability to remodel their surrounding ECM
through the action of MMPs. MMPs are divided into five classes based
on their structure and substrate specificities: collagenases, gelatinases,
stromelysins, membrane type MMPs (MT-MMPs), and others. Active
MMPs are inhibited by tissue inhibitors (TIMPs).80,81 During arterial
wound healing (with or without stent implantation), the gelatinases,
MMPs-2 and -9, and later MT1-MMP, are implicated in the migration
and proliferation of VSMCs, and degradation of ECM components in
various animals and man. Nevertheless, knockout of MMP-2, MMP-9,
and MMP-14 delay intimal thickening formation in mouse models,
which shows that each is necessary.80,81 More recently, it has been
shown thatMMP-3 is also involved in the activation of MMP-9-mediated
VSMC migration and neointimal formation in mice.82 These studies in
animals andman indicate that severalMMPs are involved in ECMremod-
elling and restenosis progression (Figure 5).
6.4 Factors influencing SMC phenotypes
The injured endothelium, platelets, and inflammatory cells release a
variety of factors influencing SMC behaviour. Many of them are well
characterized such as PDGF-BB, FGF-2, IGF, TGF-b, angiotensin II,
endothelin-1, and interleukins. The chance to orchestrate SMC switch-
ing, thus influencing in-stent restenosis may be instrumental for the de-
velopment of preventing and therapeutic strategies. Inhibitors of SMC
proliferation and/or differentiation factors, e.g. heparin and TGF-b,
and stimulators of SMC proliferation and/or dedifferentiation factors,
e.g. PDGF-BB and FGF-2 are among the most studied agents employed
to modulate SMC phenotype. Some of them show species-specific and
phenotype-dependent effects.
Heparin andTGF-b inhibit proliferation and increasedifferentiation in
pig SMCs39 regardless of their phenotype, while only R-SMCs are
affected in the bovine model.38 The effects on cell morphology are
absent or partial depending on the initial phenotype; moreover, a com-
plete morphological switch is never achieved.We studied the effects of
different cytostatic drugs on porcine S- and R-SMC. Although imatinib
may represent valid therapeutic options by promoting SMC quiescence
and differentiation,83 SMCs regain a contractile phenotypeonly partially.
In human SMCs, only E-SMCs show a strong response to PDGF-BB
and FGF-2 in terms of proliferation and to PDGF-BB alone in terms of
migration.40 In pig, SMCs both increase migration and proliferation
and induce a switch from the S- to theR-phenotype.39 ThePDGF-driven
phenotypic switch is accompanied by an up-regulation of S100A451 as
well as connexin 43. PDGF–BB induced S-to-R phenotypic change is
preventedbya reductionof connexin43expression suggesting that con-
nexin 43 may play a role in the development of restenosis.65 We have
also observed that co-culture of ECs with porcine S-SMCs induces a
transition towards the R-phenotype; in this experiment, ECs never
reached quiescence thus mimicking a dysfunctional endothelium.39
Taken together, these studies offer insights onhowmicroenvironmental
factors can influence essential cellular processes (i.e. proliferation, mi-
gration, and dedifferentiation) and selectively modulate the behaviour
of distinct SMC subpopulations.
7. Shortcomings of existing animal
models
One of the major criticisms of the preclinical animal studies of DES that
were carried out in the porcinemodel was their inability to predict DES
associated late stent thrombosis. Thiswasdue to the lackof appreciation
of differences in the healing responses of the arterial wall when com-
pared with BMS at 28 days. Animal studies are performed in healthy
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juvenile animals which heal within 28 days following BMS implantation
and in DES although there is persistence of peristrut fibrin, nevertheless
there is complete endothelialization observed even at 28 days. Endothe-
lialization has been shown to be significantly more rapid in the porcine
than in the rabbit model, however, both heal rapidly when compared
withman,where endothelialization is only complete by 3–4months fol-
lowing BMS implantation. Another aspect that deserves mention is the
presence of underlying atherosclerosis in man and other plaque
factors such as thrombus, aswell as the presence of lipid core likely influ-
ences the drug retention and therefore healing which is also further
delayedwith incomplete endothelialization seenevenup to1 year, espe-
cially in patients presenting with acute coronary syndrome when com-
pared with stable angina.
8. Untoward effects of DES
Restenosis in BMS is usually diffuse, whereas following DES, the process
is very focal and is believed tobe the resultof excessive injury inboth, but
inDES theremaybenon-uniformdrugdistributiondue to the increase in
inter-strut distance. Arterial healing is generally delayed in DES when
compared with BMS, which is characterized by the decrease in intimal
thickening due to a suppression of SMCs with persistence of fibrin de-
position in the peristrut regions and poor endothelialization since the
anti-proliferative effects of drugs are not specific to SMCs but effect
EC re-growth (Figure 6). Although restenosis was dramatically
reduced with the use of DES, these beneficial effects were at the cost
of a higher incidence of late and very late stent thrombosis. Late stent
thrombosiswas attributed todelayedhealing and thepresenceofuncov-
ered struts due to the decrease in endothelialization of stent struts. The
use of permanent polymers was also attributed to excessive
inflammation and hypersensitivity reaction. The second generation of
stents has reduced late stent thrombosis likely as a result of both thin
struts and better polymers. Bioabsorbable polymer usage has also
been associated with the decrease in late stent thrombosis and reduc-
tion in target lesion revascularization (Leaders trial). Restenosis al-
though dramatically reduced by DES in the first year, but has gradually
increased with time in both the first and second generation of DES.
9. Conclusion
Besides differences in neointimal formation after stent implantation in
humans and animals, experiments in pig and rabbit havebeen instrumen-
tal to decipher the complex mechanisms underlying the restenotic
process. Stent implantation leads to a series of early events including
endothelium injury, platelet deposition, and inflammatory response.
These events are associated with the mechanical stretch and low
shear stress induced by stent struts which promote SMC accumulation
in the intima. Therefore, SMCsplayacentral role in the granulation tissue
development, wound healing, tissue remodelling, and finally progression
to in-stent restenosis. During these processes, SMCs undergo profound
modifications. They acquire high proliferative and migratory capabilities
and switch to a synthetic phenotype.Many studies, including ours, on ar-
terial SMC heterogeneity yield the isolation in vitro of distinct SMC sub-
populations and the identification of genes/proteins typical of the
atheroma-prone phenotype. The identification of different SMCpheno-
types that can be characterized by specific genes and/or proteins better
clarify the role of SMCs in intimal thickening formation. In particular,
investigations aimed at specifically influencing the cellular processes
(i.e. proliferation, migration, and differentiation) of the atheroma-prone
SMC (e.g. porcine R-SMCs) accumulation in the intima, without altering
Figure 6 Delayed arterial healing followingDES vs. BMS implantation. Time course of arterial healing in BMS, paclitaxel-eluting stents (PES: TaxusDES),
and sirolimus-eluting stents (SES: CypherDES) from 1 to 8months after stent implantation. Although some peristrut inflammation is observed in BMS at 1
month, complete arterial healing, including a well-established neointimal layer, is seen at 3 and 8 months’ duration. PES shows early fibrin deposition sur-
rounding stent struts (*),whichpersists up to8months, as a signof delayedhealing. In contrast, SES showsthepredominanceof inflammatory cells, including
giant cell formation (black arrowheads), at early time points (1 and 3 months), whereas fibrin deposition is stronger at 8 months. Reproduced with
permission from Luscher et al.84
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the behaviour of quiescent contractile SMCs (e.g. porcine S-SMCs)
could be instrumental to design human-tailored therapies that prevent
in-stent restenosis. S100A4 identified as being typical of the atheroma-
prone phenotype and relevant to the human restenotic lesions repre-
sents a potential target for this purpose.
Through a greater understanding of the mechanisms responsible for
restenosis following BMS, DES evolved and these have successfully
reduced restenosis. However, even DES have their short comings in-
cluding late stent thrombosis and increasing target vessel revasculariza-
tion with time; further improvement in stents are needed and perhaps
the totally bioerodable scaffold with improvements and newer agents
that target only SMCsmay become the next revolution in interventional
technology.
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